newsfilter
← Latest News
Business Wire·

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) Biologics